Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05947474 · ClinicalTrials.gov registry record · Phase 1
ORB-011 In Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Cancer, sponsored by Orionis Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT05947474: Active Phase 1 study of Advanced Solid Cancer, sponsored by Orionis Biosciences.
NCT05947474 is a Phase 1 study of Advanced Solid Cancer that is active but no longer recruiting, run by Orionis Biosciences. The registered enrollment target is 55 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05947474, a Phase 1 study of Advanced Solid Cancer, is active but no longer recruiting, sponsored by Orionis Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical research study is to determine if an investigational new drug, named ORB-011, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.
Primary Outcome
Number of participants with adverse events (AE) in patients dosed with ORB-011
Conditions Studied
Interventions
- DRUG ORB-011
Study Locations (2)
Arizona
- Honor Health Research Institute - Scottsdale
Texas
- MD Anderson Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT05947474 still lists
NCT05947474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Advanced Solid Cancer appearing as the primary indexed condition, and to 1 intervention - of which ORB-011 is the first listed.
NCT05947474 reports a single indexed study location in Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT05947474 about?
NCT05947474 is a clinical study titled "ORB-011 In Patients With Advanced Solid Tumors". The goal of this clinical research study is to determine if an investigational new drug, named ORB-011, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by ...
What is the current status of trial NCT05947474?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2023-08-21. Estimated completion is 2026-03.
What conditions does trial NCT05947474 study?
This clinical trial studies the following conditions: Advanced Solid Cancer.
What interventions are being tested in trial NCT05947474?
The interventions under investigation include: ORB-011 (DRUG).
Who is sponsoring clinical trial NCT05947474?
This trial is sponsored by Orionis Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05947474 being conducted?
This trial has 2 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05947474's enrollment target sits among peer trials
55 918th of 2000 higher than 1,070 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI